Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683046 · ClinicalTrials.gov registry record · Phase 2
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT00683046 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 204 participants.
The verdict
NCT00683046, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
Objectives: 1. To evaluate disease free survival after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies. 2. To evaluate the incidence and severity of acute and chronic GVHD after Campath 1H-based in vivo T-cell depletion, in patients with hematologic malignancies undergoing non-myelo-ablative stem cell transplantation. 3. To evaluate engraftment and chimerism after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Campath
- DRUG Stem cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2001-11 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00683046
The ClinicalTrials.gov registry entry for NCT00683046 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fludarabine is the first listed.
NCT00683046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00683046 about?
NCT00683046 is a clinical study titled "T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies". Objectives: 1. To evaluate disease free survival after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies. 2. To evaluate the incidence and severity of acute and chronic GVHD after Campath 1H-based in vivo T-...
What is the current status of trial NCT00683046?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2001-11. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00683046?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Campath (DRUG), Stem cells (DRUG).
Who is sponsoring clinical trial NCT00683046?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.